Brief: Oncolytics Biotech Announces Phase 2 Trial Evaluating Pelareorep-Anti-Pd-1 Combination Treatment
25/06/2020 12:05
June 25 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® ANNOUNCES INVESTIGATOR SPONSORED PHASE
2
TRIAL EVALUATING PELAREOREP-ANTI-PD-1 COMBINATION TREATMENT IN
TRIPLE-NEGATIVE BREAST CANCER
Source text for Eikon: ID:nCNWr4fKPa
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer